Skip to content

Safety and efficacy of injection of Umbilical Cord Blood Serum derived exosomes for skin lesions in patients with chronic psoriasis

Safety and efficacy of injection of Umbilical Cord Blood Serum derived exosomes for skin lesions in patients with chronic psoriasis(Phase ? of clinical trial)

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221130056672N4
Enrollment
30
Registered
2024-01-21
Start date
2024-01-20
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis. Psoriasis

Interventions

Intervention 1: The first intervention group: under treatment with local injection of exosome (derived from cord blood serum purchased from Apsa company) with a concentration of 50 micrograms per mill

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age older than 18 years Patients with chronic plaque psoriasis for at least 6 months PASI index 3 to 12 Lesion intensity 1 to 3 (rating 0 to 5) Lack of proper response to standard treatments including local treatments, light therapy and systemic treatments Not creating new lesions or increasing the size of previous lesions in the last 3 months Skin lesion with BSA higher than 10%

Exclusion criteria

Exclusion criteria: Use of systemic immunosuppressive drugs in the last 4 weeks and topical drugs except emollients in the last 2 weeks Severe underlying disease (liver-kidney and heart failure) Increase of liver enzymes > 3 times normal and creatinine > 2 Patients with diabetes mellitus, patients with a history of hepatitis B, C or HIV Pregnant and nursing mothers Patients with immunodeficiency, patients with malignancy, presence of debilitating disease, presence of active infection

Design outcomes

Primary

MeasureTime frame
PASI index:Psoriasis Area Severity Index (PASI). Timepoint: The measurement will be at the beginning of the study (before the start of the intervention) and 7, 14, 21, 30 and 60 days after the first injection. Method of measurement: analysis and impact of data using biometric like High-Frequency Sonography.

Secondary

MeasureTime frame
Safety. Timepoint: At the beginning of the intervention, in each re-visit session and one month after the end of the treatment period (four months after the start of the treatment). Method of measurement: Patient history.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEhsan Taghiabadi

Tehran University of Medical Sciences

etaghiabadi@sina.tums.ac.ir+98 21 2665 7438

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026